7MM autism spectrum disorder market to be valued at $2b by 2034

Thanks to the anticipated launch of five late-stage pipeline products.

The autism spectrum disorder (ASD) market across the seven major markets (7MM) is expected to reach $2b in 2034 at a compound annual growth rate of 18.7%, according to a GlobalData report.

The sector’s expansion is attributed to the anticipated launch of five late-stage pipeline products during the forecast period.

“In order of entry, these will be Curemark’s CM-AT/ LUMINENZ-AT, Yamo Pharmaceuticals’ L1-79 (metyrosine), and MapLight Therapeutics’ ML-004 (zolmitriptan),” said Christie Wong, Managing Neurology Analyst at GlobalData.

The products are expected to drive combined sales of approximately $1.7b by 2034 in the 7MM, accounting for 8.4% of the ASD market.

However, the continued use of inexpensive generic products may limit growth, Wong added.

7MM =  US, France, Germany, Italy, Spain, UK, and Japan